🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesMy blood pressure normalization journey — off 2 antihypertensives

My blood pressure normalization journey — off 2 antihypertensives

BethLabQueen Sat, May 16, 2026 at 5:28 PM 27 replies 640 viewsPage 1 of 6
BethLabQueen
Senior Member
1,234
5,678
May 2024
Virginia
Online
May 16, 2026 at 5:28 PM#1

Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

The bit I cannot resolve on my own is how much of the SELECT benefit is plausibly independent of the weight loss, and whether that distinction changes anything practical.

Practical detail welcome, however dull — the duller the better.

1 21maya_sedona
Reply Quote Save Share Report
Dr.PeteFamMed
Senior Member
2,012
9,234
Jan 2024
Minneapolis, MN
May 16, 2026 at 7:44 PM#2
BethLabQueen said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling, reduces NLRP3 inflammasome activation, and decreases monocyte/macrophage adhesion to endothelium[1].

Clinical correlates: hsCRP reduction of 30-60% (consistently seen across trials), reduced carotid intima-media thickness, and decreased coronary plaque inflammation on PET imaging.

These anti-inflammatory effects likely contribute to the cardiovascular benefit seen in SELECT — and may explain benefits beyond what weight loss alone would predict.

References:
[1] Hogan AE, et al. Diabetologia. 2014;57(4):781-784.
50 20tommy_boulder, hyun_seoul, jim_asheville and 47 others
Reply Quote Save Share Report
MikeNYC_runner
Member
378
1,678
Jul 2024
New York, NY
May 16, 2026 at 10:00 PM#3
Dr.PeteFamMed said:
Anti-inflammatory mechanisms of GLP-1 agonists and cardiovascular risk: beyond weight loss, GLP-1R activation directly suppresses NF-κB signaling,…

Lp(a) and cardiovascular risk: a nuance that matters. Unlike most lipid markers, Lp(a) is 90%+ genetically determined and doesn't really change with weight loss or GLP-1 therapy.

My Lp(a) has remained at 81 nmol/L across all time points. If yours is elevated (>50 nmol/L), you need additional risk mitigation strategies regardless of your GLP-1 response. Don't assume your medication is covering all cardiovascular risk factors.

Last edited: May 17, 2026 at 12:00 AM
49 19Dr.ObesityMed, HealthEcon_DC, PedsEndoPhilly and 46 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
anna.melb_AU
Member
678
2,890
Apr 2024
Melbourne, AU
May 17, 2026 at 12:16 AM#4
BethLabQueen said:
Prescribed on cardiovascular grounds rather than for weight, and almost everything written for patients assumes the opposite.

This is my experience too, for whatever a second data point is worth. Nothing to add that would improve it.

48 18tammy_FL, Dr.LipidDallas, alex_tucson and 45 others
Reply Quote Save Share Report
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
May 17, 2026 at 1:48 PM#5

From the other side of the consultation, briefly.

I'm 55 years old and want to share my perspective on cardiovascular risk as an older member of this community.

My doctor was initially hesitant because of my age, but the SELECT trial included patients up to 72 and showed consistent benefit across age groups. We started at the lowest dose with closer monitoring.

8 months later: down 55 lbs, off atorvastatin, A1C from 7.0% to 5.2%. My cardiologist is thrilled. cardiovascular risk is absolutely relevant for older adults — don't let anyone tell you otherwise.

Last edited: May 17, 2026 at 4:48 PM
47 17kate.chem, DataDave, Dr.GutHealth and 44 others
Reply Quote Save Share Report
1236

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register